| Drug Candidate | Indication | Discovery / Lead Optimization |
IND Enabling | Phase 1A | Phase 1B | Collaborations |
|||||||||
| NXP800 | ARID1a-mutated Ovarian Cancer | ||||||||||||||
| Fast Track Designation, Orphan Drug Designation |
 |
||||||||||||||
| Cholangiocarcinoma (IST) |  |
||||||||||||||
| Orphan Drug Designation |
|||||||||||||||
| NXP900 | YES1/SRC- driven Solid Tumors (monotherapy) |
||||||||||||||
| All comer dose escalation ongoing |
|||||||||||||||
| ALK positive / EGFR mutated NSCLC (combination) |
|||||||||||||||
